Immutep (IMM) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Immutep Ltd Advances Efti in Cancer Treatment TrialsNovember 22 at 5:37 AM | markets.businessinsider.comImmutep Limited Passes All AGM ResolutionsNovember 22 at 12:37 AM | markets.businessinsider.comImmutep Ltd Sees Increased Stake from Regal FundsNovember 18, 2024 | msn.comAnalysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Immutep Ltd (OtherPRRUF)November 18, 2024 | markets.businessinsider.comImmutep price target raised to $7 from $6 at BairdNovember 17, 2024 | markets.businessinsider.comImmutep Reports Promising Phase II Sarcoma Trial ResultsNovember 16, 2024 | markets.businessinsider.comImmutep Reports Promising Phase II Sarcoma Trial ResultsNovember 16, 2024 | markets.businessinsider.comImmutep’s Promising Lung Cancer Trial ResultsNovember 16, 2024 | markets.businessinsider.comImmutep’s Promising Lung Cancer Trial ResultsNovember 16, 2024 | markets.businessinsider.comImmutep Limited: Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung CancerNovember 15, 2024 | finanznachrichten.deImmutep stock jumps 11% on positive data for eftilagimod alphaNovember 15, 2024 | msn.comImmutep announces data from INSIGHT-003 trialNovember 14, 2024 | markets.businessinsider.comImmutep data from Phase II trial presented at CTOSNovember 14, 2024 | markets.businessinsider.comImmutep’s Cancer Trial Shows Promising Survival ResultsNovember 14, 2024 | markets.businessinsider.comImmutep Ltd Reports Promising Results in Sarcoma TrialNovember 14, 2024 | markets.businessinsider.comCanaccord Genuity Sticks to Its Buy Rating for Aroa Biosurgery Ltd (ARX)November 13, 2024 | markets.businessinsider.comCanaccord Genuity Sticks to Its Buy Rating for PYC Therapeutics Limited (PYC)November 13, 2024 | markets.businessinsider.comImmutep reports Q1 cash receipts from custmers $20,000October 29, 2024 | markets.businessinsider.comImmutep Ltd Reports Positive Advances in Cancer TrialsOctober 29, 2024 | markets.businessinsider.comImmutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024October 28, 2024 | finance.yahoo.comImmutep Faces Cybersecurity Threats: Potential Delays and Liabilities in Product DevelopmentOctober 23, 2024 | markets.businessinsider.comImmutep Limited Announces 2024 AGM DetailsOctober 22, 2024 | markets.businessinsider.comImmutep Limited Announces 2024 Financial PerformanceOctober 22, 2024 | markets.businessinsider.comImmutep Strengthens Transparency with Updated Governance DisclosureOctober 22, 2024 | markets.businessinsider.comImmutep Flat on Test ResultsOctober 17, 2024 | baystreet.caImmutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of TrialOctober 17, 2024 | markets.businessinsider.comImmutep concludes participant enrolment in Phase II breast cancer trialOctober 4, 2024 | msn.comImmutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast CancerOctober 3, 2024 | markets.businessinsider.comHere's why this beaten-up ASX All Ordinaries stock is surging 48% todaySeptember 24, 2024 | msn.comImmutep snaffles A$3.6M from French government for R&DSeptember 24, 2024 | msn.comBuy Rating Affirmed for Immutep on Promising Efti Outlook Despite Mixed Study InterpretationsSeptember 19, 2024 | markets.businessinsider.comWhy Cettire, Immutep, Paladin Energy, and Westgold shares are sinking todaySeptember 15, 2024 | msn.comAlive and Kicking: Respiri promises breath of life to bottom line after inking US distribution dealSeptember 15, 2024 | msn.comImmutep Ltd Webcast Presentation TranscriptSeptember 14, 2024 | gurufocus.comImmutep Ltd Clinical Results Webinar TranscriptSeptember 14, 2024 | gurufocus.comImmutep Ltd (PRRUF) Receives a Buy from WilsonsSeptember 12, 2024 | markets.businessinsider.comImmutep’s Innovative LAG-3 Focused Therapies Poised to Transform Advanced Cancer Treatments: A Buy Rating OverviewSeptember 11, 2024 | markets.businessinsider.comImmutep Ltd (YP1A.HM)August 29, 2024 | uk.finance.yahoo.comImmutep Ltd (YP1B.BE)August 29, 2024 | uk.finance.yahoo.comImmutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024August 20, 2024 | finance.yahoo.comASX Health Stocks: Inoviq’s tech boosts early detection of Parkinson’s diseaseAugust 20, 2024 | msn.comImmutep Ltd (PRRUF) Gets a Buy from Canaccord GenuityAugust 19, 2024 | markets.businessinsider.comIMMP Sep 2024 5.000 call (IMMP240920C00005000)August 18, 2024 | finance.yahoo.comBuy Rating Justified by Promising Drug Pipeline and Financial Health at Praxis Precision MedicinesAugust 16, 2024 | markets.businessinsider.comBoth retail investors who control a good portion of Immutep Limited (ASX:IMM) along with institutions must be dismayed after last week's 10% decreaseAugust 9, 2024 | finance.yahoo.comImmutep to Participate in Upcoming Investor ConferencesAugust 7, 2024 | finance.yahoo.comImmutep Limited: Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung CancerJuly 22, 2024 | finanznachrichten.deGuess which ASX healthcare stock is surging on big FDA newsJuly 22, 2024 | msn.comWhy 29Metals, Immutep, Insignia, and Perenti shares are pushing higher todayJuly 22, 2024 | msn.comImmutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune DiseasesJuly 19, 2024 | finance.yahoo.com Get Immutep News Delivered to You Automatically Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter. Email Address Buffett Dumps $982 Million in BofA Stock—What Does He Know? (Ad)Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention. Get your FREE, no-obligation Wealth Protection Guide now IMM Media Mentions By Week IMM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMM News Sentiment▼0.070.49▲Average Medical News Sentiment IMM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMM Articles This Week▼91▲IMM Articles Average Week Get Immutep News Delivered to You Automatically Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AGNPF News Today AKBLF News Today DRTSW News Today ARNI News Today ASPHF News Today ASCLF News Today AVCTF News Today AWKNF News Today AXIM News Today BRRGF News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:IMM) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immutep Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immutep With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMM Stock Alerts